Author/Authors :
Ghasemiyeh, Parisa Department of Clinical Pharmacy - School of Pharmacy - Shiraz University of Medical Sciences - Shiraz, Iran , Mortazavi, Negar Department of Clinical Pharmacy - School of Pharmacy - Shiraz University of Medical Sciences - Shiraz, Iran , Karimzadeh,Iman Department of Clinical Pharmacy - School of Pharmacy - Shiraz University of Medical Sciences - Shiraz, Iran , Vazin, Afsaneh Department of Clinical Pharmacy - School of Pharmacy - Shiraz University of Medical Sciences - Shiraz, Iran , Mahmoudi, Laleh Department of Clinical Pharmacy - School of Pharmacy - Shiraz University of Medical Sciences - Shiraz, Iran , Moghimi-Sarani, Ebrahim Department of Psychiatry - Research Center for Psychiatry and Behavioral Sciences - Shiraz University of Medical Sciences - Shiraz, Iran , Sadeghi, Ashkan Mohammad Department of Clinical Pharmacy - School of Pharmacy - Shiraz University of Medical Sciences - Shiraz, Iran , Shahisavandi, Mina Department of Clinical Pharmacy - School of Pharmacy - Shiraz University of Medical Sciences - Shiraz, Iran , Kheradmand, Ali Department of Psychiatry - Taleghani Hospital Research Development Committee - Medical School - Shahid Beheshti Medical University - Tehran, Iran , Mohammadi-Samani, Soliman Pharmaceutical Sciences Research Center - School of Pharmacy - Shiraz University of Medical Sciences - Shiraz, Iran
Abstract :
Coronavirus disease 2019 (COVID-19) management in patients with predisposing psychiatric
disorders would be challenging due to potential drug-drug interactions (PDDIs) and precipitation
of their disease severity. Furthermore, COVID-19 itself might precipitate or induce unpredicted
psychiatry and neuropsychiatry complications in these patients. In this literature review study,
the psychological impacts of COVID-19 and major psychiatric adverse drug reactions (ADRs)
of COVID-19 treatment options have been discussed. A detailed Table has been provided to
assess potential drug-drug interactions of COVID-19 treatment options with psychotropic
medications to avoid unwanted major drug-drug interactions. Finally, potential mechanisms of
these major drug-drug interactions and possible management of them have been summarized.
The most common type of major PDDIs is pharmacokinetics. Hydroxychloroquine/chloroquine
and lopinavir/ritonavir were the most involved anti-COVID-19 agents in these major PDDIs.
Keywords :
Pharmacokinetics , Drug-drug interactions , Adverse drug reactions , Psychotropic medication , COVID-19
